Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Status:
Completed
Trial end date:
2019-02-21
Target enrollment:
Participant gender:
Summary
This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non
Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1)
and dose expansion (Part 2). In Part 2, participants will receive the dose level identified
in Part 1.